Versant Ventures — Full Portfolio
73 tracked investments · listed companies and verified rows first
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)HBM PartnersAmzak HealthAvoro Capital AdvisorsGV (Google Ventures)+1 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer.
BiotechHealthtechMedical DevicesPhiladelphia, US
Board seatCarlo Rizzuto· per SEC Form D · $160M raise · filed Mar 2021
Co-investorsCasdin Capital
Co-investorsRA Capital
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)
BoardPatrick Heron(Director)inCarl Gordon(Director)Thomas Street Address 1 Woiwode(Director)Saqib Islam(Director)
Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersNew Leaf Venture PartnersOrbiMedVivo Capital
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Board seatTom WoiwodeAlex Mayweg· per SEC Form D
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVenrockFidelity InvestmentsInvusQatar Investment Authority
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Board seatClare Ozawa· per SEC Form D
Co-investorsREDMILEBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvusJanus Henderson Investors+4 more
AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
BiotechNatick, US
Catherine Pearce(CEO & Founder)DHSc(Founder)Justin R Thompson(Founder)in
Co-investorsWestlake BioPartnersWestlake Village BioPartners
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)
Co-investorsWestlake Village BioPartners
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)Michael Ross(Director)
Co-investorsQiming Venture PartnersSV Health InvestorsAlexandriaDementia Discovery FundQiming HealthcareQiming Venture Partners USA
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactDCVC BioLilly Asia VenturesDCVC (Data Collective)
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.
BiotechDeep TechMedical Devices
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in
Co-investorsForbionAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundSanofi VenturesForbion
iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.
BiotechHealthtechMedical Devices
James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)Paul Firuta(COO)Alex Monteith(Chief Business Officer)David Garrett(CFO)Gabriel M. Cohn(Chief Medical Officer)
Co-investorsOrbiMedLYFE Capital
Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.
AI & Machine LearningBiotechMedical Devices
Co-investorsTaiho Ventures, LLCAbbVieMubadala Capital
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)Philip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)
Co-investorsForesite CapitalSixty Degree CapitalCowen Healthcare InvestmentsGoldman Sachs
Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches.
AI & Machine LearningBiotechDeep Tech
Andrew Phillips(President and Chief Executive Officer)
Co-investorsNew Enterprise Associates (NEA)
RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases.
BiotechHealthtech
Bill Sellers(Scientific Founder and Director Cancer Program, Broad Institute)Stephen Yoder(President & CEO)
Co-investorsNew Enterprise Associates (NEA)Sixty Degree Capital
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)Newman Yeilding(Chief Medical Officer)in
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)RTW Investments L.P.TPG
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)Paul Kang(Director, Founder)
Co-investorsSamsara BioCapital
858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)James Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)
BoardAli Behbahani(Director)
Board seatClare OzawaMonal MehtaCarlo Rizzuto· per SEC Form D · $50.4M raise · filed Jul 2024
Co-investorsNew Enterprise Associates (NEA)Versant Venture Capital
BiotechStony Brook, US
Elizabeth Buck(Executive Officer)David M Epstein(Executive Officer, Director)
BoardAlexander Mayweg(Director)inGarry E Menzel(Director)
Board seatBrad BolzonAlex Mayweg· per SEC Form D · $12.1M raise · filed Jan 2018
Co-investorsNew Enterprise Associates (NEA)
Seattle, US
Eric Dobmeier(Executive Officer, Director)Sam Hall(Director)
BoardSrini Akkaraju(Director)inJeremy Caldwell(Director)
Board seatJerel Davis· per SEC Form D · $65M raise · filed Aug 2019
Co-investorsSamsara BioCapital
HealthtechIrvine, US
Toby Thomas(Executive Officer)Alec Cunningham(Executive Officer, Director)Cindy Becker(Executive Officer)Samuel R. Willcoxon(Executive Officer, Director)
BoardTimothy Petersen(Director)in
Board seatBarbara Lubash· per SEC Form D · $15.6M raise · filed Jul 2015
Co-investorsArboretum Ventures
Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.
BiotechHealthtechMedical DevicesCincinnati, US
Mike Hooven(Chairman, President and CEO)inTimothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)Norman R. Weldon(Director)
Board seatBeckie Robertson· per SEC Form D · $30M raise · filed Jan 2026
Co-investorsAngel Physicians FundCincyTechLightship CapitalOhio Innovation FundMagnetar AI Ventures
South San Francisco, US
Board seatJerel DavisAlex Mayweg· per SEC Form D · $72M raise · filed Mar 2024
Co-investorsMPM BioImpact
South San Francisco, US
Board seatJerel DavisCarlo Rizzuto· per SEC Form D · $150.7M raise · filed Mar 2021
BiotechSan Diego, US
ERIC FISCHER(Director)
BoardTHOMAS WOIWODE(Director)inJEREMY CALDWELL(Executive Officer, Director)
Board seatClare Ozawa· per SEC Form D · $50M raise · filed Sep 2020
Boston, US
Board seatCarlo Rizzuto· per SEC Form D · $107M raise · filed Jan 2024
Co-investorsPolaris Partners
Cambridge, US
Board seatClare Ozawa· per SEC Form D · $30.3M raise · filed Sep 2022
BiotechSan Diego, US
Petpiboon Prasit(Director)
BoardJeremy Caldwell(Executive Officer)Bradley Bolzon(Director)
Board seatJerel DavisClare Ozawa· per SEC Form D · $59.3M raise · filed Jun 2018
BiotechLittleton, US
Andrew Phillips(Executive Officer, Director)
BoardAli Behbahani(Director)in
Board seatCarlo Rizzuto· per SEC Form D · $60M raise · filed Mar 2026
Co-investorsNew Enterprise Associates (NEA)
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)Anthony Coyle(Executive Officer, Director)Christopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Board seatCarlo Rizzuto· per SEC Form D · $80M raise · filed Apr 2020
Co-investorsAccess BiotechnologyPolaris Partners
BiotechPotomac, US
Cristina Rondinone(Executive Officer, Director)
BoardMickey Kim(Director)Soumitra Ghosh(Director)
Board seatCarlo Rizzuto· per SEC Form D
BiotechCoronado, US
GERALD HORN(MANAGER)MARK LESTER(MANAGER)JAMES McCOLLUM(MANAGER)
Board seatClare Ozawa· per SEC Form D · $83.5M raise · filed Mar 2023
BiotechNew York, US
Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)
Board seatBrad BolzonJerel Davis· per SEC Form D · $42.1M raise · filed Jan 2019
Co-investorsBrace PharmaF-Prime CapitalFACIT (Fight Against Cancer Innovation Trust)Foothill VenturesVenture OntarioOrbiMed+1 more
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Judith Lieberman(Co-Founder, MD, PhD)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)
BoardJosh Resnick(Director)
Board seatMarkus WarmuthJerel Davis· per SEC Form D
Co-investorsAndreessen HorowitzGV (Google Ventures)RA CapitalSoftBank Vision Fund
BiotechIrvine, US
Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)
BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)
Co-investorsEvidity Health CapitalFlying L PartnersHEALTHCARE ROYALTY PARTNERSSV Life SciencesVersant Venture AIV Holdings
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpacevenBio Partners
Baseline is a biotech company focused on metabolism, obesity, incretins, and GLP-1-based strategies for substance use disorders, drawing on drug development and addiction medicine expertise.
BiotechDigital HealthHealthtech
Co-investorsVery Serious Ventures
Co-investorsSamsara BioCapitalScion Life Sciences
Co-investorsKhosla VenturesSR One Capital Management
Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.
BiotechHealthtechBrighton, GB
John Ford(Co-founder)Martin Gosling(Founder)in
Co-investorsEpidarex Capital
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersPfizer Venture Investments+5 more
HealthtechMenlo Park, US
Eugene de Juan, Jr., M.D.(Director)K. Angela Macfarlane(Executive Officer, Director)John F. Maroney(Executive Officer, Director)
BoardRobert C. Bellas, Jr.(Director)Hanson S. Gifford III(Executive Officer, Director)Jim Glasheen(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersLightstone Ventures
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtech
Co-investorsLongitude CapitalOrbiMedWellington Management
Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.
HardwareHealthtechMedical DevicesIrvine, US
William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)
BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)
Co-investorsGilde HealthcareUS Venture PartnersVensana Capital
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsWestlake Village BioPartnersOsage University Partners
BiotechCambridge, US
Alexander Mayweg(Executive Officer, Director)Anna Kohlmann(Executive Officer)
BoardAli Behbahani(Director)in
Co-investorsNew Enterprise Associates (NEA)
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupRTW Investments L.P.Sectoral Asset Management
Eden Prairie, US
Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)Kirk Nielsen(Director)
Co-investorsSanderling VenturesNew Enterprise Associates (NEA)
HealthtechNewark, US
John Hendrick(Executive Officer, Director)Tim Dumke(Executive Officer)
BoardStephen Martin(Director)William Link(Director)Ryan Schwarz(Director)Steven Waite(Director)
Co-investorsSV Health InvestorsMPM BioImpactOxford Finance LLCSV Life Sciences
BiotechDoylestown, US
Osvaldo Flores(Executive Officer, Director)Daniel E. Geffken(Executive Officer)George Hartman(Executive Officer)Gregory Korbel(Executive Officer)
BoardTim Shannon(Director)Scott Rocklage(Director)
Co-investorsBioAdvanceCanaan Partners5AM Ventures
A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments.
BiotechHealthtechSan Francisco, US
Jeffrey Nau(Executive Officer, Director)inMark A. Murray(Executive Officer, Director)D. Michael Ackermann(Director)
BoardWilliam J Link(Director)Ali Behbahani(Director)in
Co-investorsFlying L PartnersNew Enterprise Associates (NEA)Versant Venture AIV HoldingsVida Ventures
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVivo Capital+1 more
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)in
BoardThomas Woiwode(Director)in
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant Venture Capital
Eye-tracking and human-state platform for clinical and consumer applications.
Co-investorsRender CapitalFlywheel Fund
T-knife develops engineered T cell therapies designed to treat patients with solid tumors, using proprietary platforms and synthetic biology to enhance T cells.
BiotechHealthtech
Elisa Kieback(Founder)in
Co-investorsAndera PartnersRA CapitalSixty Degree CapitalFidelity Investments
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoBiotechnology Value FundCasdin CapitalFonds de solidarité FTQ+4 more
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.